Researchers led by Kyoto University and Osaka University have identified the PRDM16 gene as a critical regulator governing the transition of human heart muscle cells from growth to functional maturation. Published in Stem Cell Reports in August 2026, the study demonstrates that PRDM16 acts as a developmental rheostat. Low levels allow cardiomyocytes to proliferate, while higher levels promote mature structural and metabolic characteristics. This discovery offers a potential pathway to enhance cardiac regeneration and engineer higher-quality tissues for drug discovery.
PRDM16 gene in cardiomyocytes
- ▪Researchers led by Yoshinori Yoshida and Antonio Lucena-Cacace identified the PRDM16 gene as a regulator governing the balance between proliferation and maturation in human iPSC-derived cardiomyocytes.
- ▪The study identifying the role of the PRDM16 gene in human heart muscle cells was published in the journal Stem Cell Reports in August 2026.
Proliferation-maturation trade-off mechanism
- ▪During embryonic development, cardiomyocytes proliferate extensively, but shortly after birth, they withdraw from the cell cycle and mature, which restricts the regenerative capacity of the adult human heart.
- ▪The PRDM16 gene acts as a developmental rheostat where low levels permit cardiomyocytes to proliferate, while higher levels facilitate structural, metabolic, and functional maturation.
PRDM16 manipulation experimental effects
- ▪Reducing PRDM16 levels in cardiomyocytes led to elevated expression of proliferative regulators like CDK1 and phospho-AKT, increased cell-cycle activity, and impaired sarcomeric organization.
- ▪Moderate overexpression of PRDM16 in cardiomyocytes suppressed cell proliferation while promoting cellular hypertrophy, increased TNNI3 expression, and enhanced oxidative metabolism.
Regenerative medicine applications
- ▪Researchers suggest that temporal manipulation of the PRDM16 pathway could help recover the proliferative potential of cardiomyocytes without permanently compromising their functional maturation.
- ▪Understanding the PRDM16 molecular checkpoint may allow scientists to develop future regenerative therapies and enhance regenerative responses in injured adult human hearts.
iPSC-derived cardiac tissue engineering
- ▪Engineered heart tissues generated from PRDM16-deficient cardiomyocytes exhibited diminished contractile performance during laboratory testing.
- ▪Cardiomyocytes generated from induced pluripotent stem cells typically remain immature, which limits their utility for translational applications like disease modeling and drug discovery.
Story comments
Loading comments…